Condition
Rectal Neoplasm Malignant
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Recruiting2
Terminated1
Completed1
Not Yet Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06831669RecruitingPrimary
Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer
NCT06896578Not ApplicableNot Yet RecruitingPrimary
Latitude - Lateral Lymph Node Attitude Study
NCT04926324Phase 1Terminated
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
NCT03587480Not ApplicableRecruitingPrimary
Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy
NCT03428529Phase 2CompletedPrimary
Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.
Showing all 5 trials